Abstract:Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic castration-resistant prostate cancer was halted because of lack of efficacy. We previously reported that KX01 binds to the colchicine site of β-tubulin and its morpholine group lies close to α-tubulin's surface. Thus, we hypothesized that enhancing the interaction of KX01 with α-tubulin could increase tubulin inhibition and synthesized a series of KX01 derivatives directed by docking studies. Among these derivatives, 8a exhibited more than 10-fold antiproliferation activity in several tumor cells than KX01 and significantly improved in vivo antitumor effects. The X-ray crystal structure suggested that 8a both bound to the colchicine site and extended into the interior of α-tubulin to form potent interactions, presenting a novel binding mode. A potential clinical candidate for cancer therapy was identified in this study.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01961?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01961</a>.Characterization of key compounds, antiproliferation activity data, MTD, table of protein crystal data collection and refinement statistics, and HPLC purity traces for key final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv">CSV</a>)Structural data for compounds 6a, 6d, and 6r (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb">PDB</a>)This article has not yet been cited by other publications.

Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer

Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer

Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 2 (DYRK2) with a Highly Selective Inhibitor for the Treatment of Prostate Cancer

Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 2 with a Highly Selective Inhibitor for the Treatment of Prostate Cancer

Synthesis and Modeling of Novel Α-Aminoalkylphosphonate Ester Derivatives As Potent Inhibitors of Prostate-Specific Antigen; A Comparison Study

Discovery of Potent, Orally Active Compounds of Tyrosine Kinase and Serine/Threonine-Protein Kinase Inhibitor with Anti-Tumor Activity in Preclinical Assays

Discovery of Pyridine Tetrahydroisoquinoline Thiohydantoin Derivatives with Low Blood-Brain Barrier Penetration As the Androgen Receptor Antagonists.

Discovery of Novel Thiohydantoin Derivatives As Full Antagonists and Efficient Degraders of Androgen Receptor

Discovery of Pyridine-2-Carboxamides Derivatives As Potent and Selective HPK1 Inhibitors for the Treatment of Cancer.

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents

Discovery and Optimization of 1-(1 H -Indol-1-yl)ethanone Derivatives As CBP/EP300 Bromodomain Inhibitors for the Treatment of Castration-Resistant Prostate Cancer

Structure-Based Discovery and Optimization of Benzo[ D]isoxazole Derivatives As Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.

Discovery of Novel 1,3-Diphenylpyrazine Derivatives As Potent S-Phase Kinase-Associated Protein 2 (skp2) Inhibitors for the Treatment of Cancer.

Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment

Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure

Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors As a Promising Strategy for Cancer Therapy

Discovery of a small-molecule NDR1 agonist for prostate cancer therapy

Discovery of novel 5-methyl-1H-pyrazole derivatives as potential anti-prostate cancer agents: design, synthesis, molecular modeling and biological evaluation.

Screening, Synthesis, Crystal Structure, and Molecular Basis of 6-Amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles As Novel AKR1C3 Inhibitors.